热门资讯> 正文
VolutionRx报告财年业绩
2026-04-01 18:33
- VolitionRX press release (VNRX): FY Revenue of $1.7M, representing growth of 40% over the previous year..
- Net loss was down 14% for the year versus 2024.
- Net cash used in operating activities was $19.7 million for the year, down 24%.
More on VolitionRX
- VolitionRx Limited secures €2M non-dilutive funding from Belgian agencies
- VolitionRx receives NYSE non-compliance notice
- Seeking Alpha’s Quant Rating on VolitionRX
- Historical earnings data for VolitionRX
- Financial information for VolitionRX
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
